MicroRNA-182对肺癌诊断价值的Meta分析  

Meta Analysis of Diagnostic Value of MicroRNA-182 in Lung Cancer

作　　者：陈孟洋 蔡会欣[2] 曹干 常文龙[2] 孙建梅[2] CHEN Meng-yang;CAI Hui-xin;CAO Gan;CHANG Wen-long;SUN Jian-mei(Chengde Medical University,Chengde,067000,China;Baoding No.1 Central Hospital,Baoding,071000,China)

机构地区：[1]承德医学院,承德067000 [2]保定市第一中心医院,保定071000

出　　处：《神经药理学报》2022年第1期11-20,共10页Acta Neuropharmacologica

摘　　要：目的:运用Meta分析方法,评价microRNA-182在肺癌中的诊断价值。方法:按制定的检索策略,全面检索中国知网、维普、万方、Pubmed、Embase、Cochrane Library、Web of Science数据库,通过纳入排除标准筛选出文献并获得相应数据,使用Stata16.0和MetaDiSc1.4进行统计学分析。结果:最终纳入18项研究,获得的数据经统计学计算出合并效应量,即合并敏感度为0.74,合并特异度为0.83,合并阳性似然比为4.44,合并阴性似然比为0.31,合并诊断比值比为14.25,综合受试者工作特征曲线下面积为0.88。结论:样本中microRNA-182对肺癌的诊断价值良好,但仍需更多的临床研究论证。Objective:The diagnostic value of microRNA-182 in lung cancer was evaluated by meta-analysis.Methods:According to the developed retrieval strategy,comprehensively search Chinese National Knowledge Infrastructure,Chongqing VIP Information,WanFang databases,PubMed,Embase,Cochrane Library,Web of Science databases.The literatures were screened by inclusion and exclusion criteria,and statistical operations were performed using Stata(version 16.0)and MetaDisc(version1.4).Results:Finally,18 studies were included.The combined effect was statistically calculated,that is,the summary sensitivity was 0.74,the summary specificity was 0.83,the summary positive likelihood ratio was 4.44,the summary negative likelihood ratio was 0.31,the summary diagnostic odds ratio was 14.25,and the area under the summary receiver operating characteristic curve was 0.88.Conclusion:MicroRNA-182 in samples has good diagnostic value for lung cancer,which still needs more clinical research.

关 键 词：microRNA-182 肺癌 诊断 

分 类 号：R969[医药卫生—药理学]